(LUCD) Lucid Diagnostics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US54948X1090

Stock: EsoGuard, EsoCheck

Total Rating 44

Risk 32

Buy Signal 0.53

Medical Devices » Health Care Equipment
Age: 4.3y

Market Cap: 156m
Avg Trading Vol: 1.05M USD

ATR: 7.70%
Peers RS (IBD): 69.64

EPS (Earnings per Share)

EPS CAGR: 55.35%
EPS Trend: 84.2%

Last SUE: 1.98
Qual. Beats: 1

Revenue

Rev. CAGR: 815.39%
Rev. Trend: 57.0%

Last SUE: 4.00
Qual. Beats: 1

Risk 5d forecast
Volatility	77.4%
Relative Tail Risk	-14.9%

Reward TTM
Sharpe Ratio	0.64
Alpha	14.68

Character TTM
Beta	0.839
Beta Downside	1.465

Drawdowns 3y
Max DD	62.35%
CAGR/Max DD	-0.03

Description: LUCD Lucid Diagnostics January 19, 2026

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage medical-diagnostics firm that markets the EsoGuard Esophageal DNA Test, which is performed on cells collected via the EsoCheck device. The test targets GERD patients at elevated risk for esophageal adenocarcinoma (EAC), aiming to detect precancerous changes early enough to reduce mortality. Lucid operates as a subsidiary of PAVmed and is headquartered in New York.

Key recent metrics (as of Q3 2024) show a cash runway of roughly $12 million and a monthly burn rate of $1.2 million, reflecting ongoing investment in FDA 510(k) clearance efforts and payer reimbursement negotiations. The U.S. market for GERD-related diagnostics is projected to grow at a 7-8% CAGR through 2030, driven by rising GERD prevalence (≈20% of adults) and increasing payer focus on early-cancer detection cost-savings. Competitors such as Cytosponge and Guardant Health are advancing similar non-invasive screening platforms, making market adoption and differentiation critical success factors.

For a deeper, data-driven view of LUCD’s valuation dynamics, you may find ValueRay’s analytical framework worth exploring.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -10.44b TTM > 0 and > 6% of Revenue
FCF/TA: -0.83 > 0.02 and ΔFCF/TA 115.2 > 1.0
NWC/Revenue: 1.95% < 20% (prev 61.47%; Δ -59.52% < -1%)
CFO/TA -0.82 > 3% & CFO -43.8m > Net Income -10.44b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.90 > 1.5 & < 3
Outstanding Shares: last quarter (108.2m) vs 12m ago 114.7% < -2%
Gross Margin: -40.22% > 18% (prev -0.53%; Δ -3969 % > 0.5%)
Asset Turnover: 3204 % > 50% (prev 18.54%; Δ 3185 % > 0%)
Interest Coverage Ratio: -5162 > 6 (EBITDA TTM -10.00b / Interest Expense TTM 2.02m)

Altman Z'' -15.00

A: 0.44 (Total Current Assets 49.8m - Total Current Liabilities 26.2m) / Total Assets 53.2m
B: -4.85 (Retained Earnings -258.1m / Total Assets 53.2m)
C: -275.4 (EBIT TTM -10.44b / Avg Total Assets 37.9m)
D: -9.43 (Book Value of Equity -257.9m / Total Liabilities 27.4m)
Altman-Z'' Score: -1874 = D

Beneish M 1.00

DSRI: 0.05 (Receivables 550.0k/39.0k, Revenue 1.21b/4.19m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.10 (AQ_t 0.01 / AQ_t-1 0.09)
SGI: 289.9 (Revenue 1.21b / 4.19m)
TATA: -195.4 (NI -10.44b - CFO -43.8m) / TA 53.2m)
Beneish M-Score: 1.67 (Cap -4..+1) = D

What is the price of LUCD shares?

As of February 07, 2026, the stock is trading at USD 1.22 with a total of 1,046,468 shares traded.
Over the past week, the price has changed by +2.52%, over one month by +7.96%, over three months by +14.02% and over the past year by +26.06%.

Is LUCD a buy, sell or hold?

Lucid Diagnostics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy LUCD.

StrongBuy: 4
Buy: 2
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the LUCD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	3.8	210.7%
Analysts Target Price	3.8	210.7%
ValueRay Target Price	1.3	4.1%

LUCD Fundamental Data Overview February 02, 2026

P/S = 35.4643
P/B = 2.159
Revenue TTM = 1.21b USD
EBIT TTM = -10.44b USD
EBITDA TTM = -10.00b USD
Long Term Debt = 2.04m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 23.2m USD (from shortTermDebt, last quarter)
Debt = 24.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.0m USD (from netDebt column, last quarter)
Enterprise Value = 133.0m USD (156.0m + Debt 24.3m - CCE 47.3m)
Interest Coverage Ratio = -5162 (Ebit TTM -10.44b / Interest Expense TTM 2.02m)
EV/FCF = -3.01x (Enterprise Value 133.0m / FCF TTM -44.2m)
FCF Yield = -33.22% (FCF TTM -44.2m / Enterprise Value 133.0m)
FCF Margin = -3.64% (FCF TTM -44.2m / Revenue TTM 1.21b)
Net Margin = -859.8% (Net Income TTM -10.44b / Revenue TTM 1.21b)
Gross Margin = -40.22% ((Revenue TTM 1.21b - Cost of Revenue TTM 1.70b) / Revenue TTM)
Gross Margin QoQ = -40.13% (prev -53.48%)
Tobins Q-Ratio = 2.50 (Enterprise Value 133.0m / Total Assets 53.2m)
Interest Expense / Debt = 8.22% (Interest Expense 2.00m / Debt 24.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.25b (EBIT -10.44b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.90 (Total Current Assets 49.8m / Total Current Liabilities 26.2m)
Debt / Equity = 0.94 (Debt 24.3m / totalStockholderEquity, last quarter 25.8m)
Debt / EBITDA = 0.00 (negative EBITDA) (Net Debt -23.0m / EBITDA -10.00b)
Debt / FCF = 0.52 (negative FCF - burning cash) (Net Debt -23.0m / FCF TTM -44.2m)
Total Stockholder Equity = 8.43m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.5k% (out of range, set to none)
RoE = -123.9k% (out of range, set to none) (Net Income TTM -10.44b / Total Stockholder Equity 8.43m)
RoCE = -99.8k% (out of range, set to none) (EBIT -10.44b / Capital Employed (Equity 8.43m + L.T.Debt 2.04m))
RoIC = 38.9k% (out of range, set to none) (NOPAT -8.25b / Invested Capital -21.2m)
WACC = 8.67% (E(156.0m)/V(180.3m) * Re(9.01%) + D(24.3m)/V(180.3m) * Rd(8.22%) * (1-Tc(0.21)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 60.96%
Fair Price DCF = unknown (Cash Flow -44.2m)
EPS Correlation: 84.18 | EPS CAGR: 55.35% | SUE: 1.98 | # QB: 1
Revenue Correlation: 57.02 | Revenue CAGR: 815.4% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.30 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+30.0% | Growth Revenue=+151.8%

Additional Sources for LUCD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle